Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT). [PDF]
J NeurolHoward JF +10 more
europepmc +1 more source
Real-world efficacy of eculizumab in generalized myasthenia gravis patients with poor early response to efgartigimod: a prospective cohort study. [PDF]
Front ImmunolAn X +5 more
europepmc +1 more source
Myasthenia gravis with dysphagia as the first symptom and misdiagnosed as anxiety-depressive state: a case report. [PDF]
Front ImmunolAili K, Maimaiti M.
europepmc +1 more source
Sequential efgartigimod and ofatumumab for stiff-person syndrome: a case report illustrating a pathophysiology-informed strategy and literature review. [PDF]
Front ImmunolYang C, Zhou J, Jiang H.
europepmc +1 more source
Treatment of anti-GAD65 antibody-positive epilepsy and cerebellar ataxia with efgartigimod: a case report and literature review. [PDF]
Front ImmunolXie L +6 more
europepmc +1 more source
Successful treatment of anti-LGI1-associated autoimmune encephalitis with efgartigimod: A case report and literature review. [PDF]
Medicine (Baltimore)Gao R, Hong Y, Zhou G.
europepmc +1 more source
Real-world study of efgartigimod in AChR antibody-positive generalized myasthenia gravis: thymus status, multi-domain symptom improvement and steroid-sparing effect. [PDF]
Front ImmunolAili K, Lu M, Zhao N, Maimaiti M.
europepmc +1 more source
Research Progress in Pharmacological Targeted Therapy for Myasthenia Gravis. [PDF]
J Inflamm ResZhou Y, Wu Y, Meng Z.
europepmc +1 more source
Case Report: Efgartigimod: a beacon of hope for overlapping stiff-person syndrome and myasthenia gravis following thymoma. [PDF]
Front ImmunolNie J, Yin W.
europepmc +1 more source
FcRn antagonist and C5 complement inhibitor as early rescue strategies in severe Myasthenia Gravis: a two-case report. [PDF]
Front ImmunolParisi M +6 more
europepmc +1 more source